Elshourbagy NA, Ames RS, Fitzgerald LR, Foley JJ, Chambers JK, Szekeres PG, Evans NA, Schmidt DB, Buckley PT, Dytko GM, Murdock PR, Milligan G, Groarke DA, Tan KB, Shabon U, Nuthulaganti P, Wang DY, Wilson S, Bergsma DJ, Sarau HM (2000). „Receptor for the pain modulatory neuropeptides FF and AF is an orphan G protein-coupled receptor”. J. Biol. Chem.275 (34): 25965–71. DOI:10.1074/jbc.M004515200. PMID10851242.
Yang HY, Iadarola MJ (May 2006). „Modulatory roles of the NPFF system in pain mechanisms at the spinal level”. Peptides27 (5): 943–52. DOI:10.1016/j.peptides.2005.06.030. PMID16443306.
Roumy M, Lorenzo C, Mazères S, Bouchet S, Zajac JM, Mollereau C (March 2007). „Physical association between neuropeptide FF and micro-opioid receptors as a possible molecular basis for anti-opioid activity”. The Journal of Biological Chemistry282 (11): 8332–42. DOI:10.1074/jbc.M606946200. PMID17224450.
Yang HY, Tao T, Iadarola MJ (February 2008). „Modulatory role of neuropeptide FF system in nociception and opiate analgesia”. Neuropeptides42 (1): 1–18. DOI:10.1016/j.npep.2007.06.004. PMID17854890.
Betourne A, Familiades J, Lacassagne L, Halley H, Cazales M, Ducommun B, Lassalle JM, Zajac JM, Frances B (November 2008). „Decreased motivational properties of morphine in mouse models of cancerous- or inflammatory-chronic pain: implication of supraspinal neuropeptide FF(2) receptors”. Neuroscience157 (1): 12–21. DOI:10.1016/j.neuroscience.2008.08.045. PMID18804517.
Cline MA, Mathews DS (2008). „Anoretic effects of neuropeptide FF are mediated via central mu and kappa subtypes of opioid receptors and receptor ligands”. General and Comparative Endocrinology159 (2-3): 125–9. DOI:10.1016/j.ygcen.2008.09.001. PMID18823989.
Mollereau C, Mazarguil H, Marcus D, Quelven I, Kotani M, Lannoy V, Dumont Y, Quirion R, Detheux M, Parmentier M, Zajac JM (2002). „Pharmacological characterization of human NPFF(1) and NPFF(2) receptors expressed in CHO cells by using NPY Y(1) receptor antagonists”. Eur. J. Pharmacol.451 (3): 245–56. DOI:10.1016/S0014-2999(02)02224-0. PMID12242085.
Fang Q, Guo J, He F, Peng YL, Chang M, Wang R (September 2006). „In vivo inhibition of neuropeptide FF agonism by BIBP3226, an NPY Y1 receptor antagonist”. Peptides27 (9): 2207–13. DOI:10.1016/j.peptides.2006.04.002. PMID16762456.
Fang Q, Wang YQ, He F, Guo J, Guo J, Chen Q, Wang R (April 2008). „Inhibition of neuropeptide FF (NPFF)-induced hypothermia and anti-morphine analgesia by RF9, a new selective NPFF receptors antagonist”. Regulatory Peptides147 (1-3): 45–51. DOI:10.1016/j.regpep.2007.12.007. PMID18276024.
Wang YQ, Guo J, Wang SB, Fang Q, He F, Wang R (July 2008). „Neuropeptide FF receptors antagonist, RF9, attenuates opioid-evoked hypothermia in mice”. Peptides29 (7): 1183–90. DOI:10.1016/j.peptides.2008.02.016. PMID18406009.
Elshourbagy NA, Ames RS, Fitzgerald LR, Foley JJ, Chambers JK, Szekeres PG, Evans NA, Schmidt DB, Buckley PT, Dytko GM, Murdock PR, Milligan G, Groarke DA, Tan KB, Shabon U, Nuthulaganti P, Wang DY, Wilson S, Bergsma DJ, Sarau HM (2000). „Receptor for the pain modulatory neuropeptides FF and AF is an orphan G protein-coupled receptor”. J. Biol. Chem.275 (34): 25965–71. DOI:10.1074/jbc.M004515200. PMID10851242.
Yang HY, Iadarola MJ (May 2006). „Modulatory roles of the NPFF system in pain mechanisms at the spinal level”. Peptides27 (5): 943–52. DOI:10.1016/j.peptides.2005.06.030. PMID16443306.
Roumy M, Lorenzo C, Mazères S, Bouchet S, Zajac JM, Mollereau C (March 2007). „Physical association between neuropeptide FF and micro-opioid receptors as a possible molecular basis for anti-opioid activity”. The Journal of Biological Chemistry282 (11): 8332–42. DOI:10.1074/jbc.M606946200. PMID17224450.
Yang HY, Tao T, Iadarola MJ (February 2008). „Modulatory role of neuropeptide FF system in nociception and opiate analgesia”. Neuropeptides42 (1): 1–18. DOI:10.1016/j.npep.2007.06.004. PMID17854890.
Betourne A, Familiades J, Lacassagne L, Halley H, Cazales M, Ducommun B, Lassalle JM, Zajac JM, Frances B (November 2008). „Decreased motivational properties of morphine in mouse models of cancerous- or inflammatory-chronic pain: implication of supraspinal neuropeptide FF(2) receptors”. Neuroscience157 (1): 12–21. DOI:10.1016/j.neuroscience.2008.08.045. PMID18804517.
Cline MA, Mathews DS (2008). „Anoretic effects of neuropeptide FF are mediated via central mu and kappa subtypes of opioid receptors and receptor ligands”. General and Comparative Endocrinology159 (2-3): 125–9. DOI:10.1016/j.ygcen.2008.09.001. PMID18823989.
Mollereau C, Mazarguil H, Marcus D, Quelven I, Kotani M, Lannoy V, Dumont Y, Quirion R, Detheux M, Parmentier M, Zajac JM (2002). „Pharmacological characterization of human NPFF(1) and NPFF(2) receptors expressed in CHO cells by using NPY Y(1) receptor antagonists”. Eur. J. Pharmacol.451 (3): 245–56. DOI:10.1016/S0014-2999(02)02224-0. PMID12242085.
Fang Q, Guo J, He F, Peng YL, Chang M, Wang R (September 2006). „In vivo inhibition of neuropeptide FF agonism by BIBP3226, an NPY Y1 receptor antagonist”. Peptides27 (9): 2207–13. DOI:10.1016/j.peptides.2006.04.002. PMID16762456.
Fang Q, Wang YQ, He F, Guo J, Guo J, Chen Q, Wang R (April 2008). „Inhibition of neuropeptide FF (NPFF)-induced hypothermia and anti-morphine analgesia by RF9, a new selective NPFF receptors antagonist”. Regulatory Peptides147 (1-3): 45–51. DOI:10.1016/j.regpep.2007.12.007. PMID18276024.
Wang YQ, Guo J, Wang SB, Fang Q, He F, Wang R (July 2008). „Neuropeptide FF receptors antagonist, RF9, attenuates opioid-evoked hypothermia in mice”. Peptides29 (7): 1183–90. DOI:10.1016/j.peptides.2008.02.016. PMID18406009.